"The New England Journal of Medicine was made great by , who banged on every important door in Boston urging researchers to admit their best studies to the journal. The journal assumed the effortless but often genuine superiority of Bostonians so well described—but also ridiculed—by Henry James. ... To some this felt like arrogance, and the journal has always been hated as well as admired. Often the motivation for such hatred may have been jealousy or resentment at failure to make it into its hallowed pages. Ingelfinger was followed by , and the journal grew richer as well as grander. The Massachusetts Medical Society, the owner of the journal, made US$88m from publishing in 2005. My guess is that the journal accounts for at least US$75m of that and that its profits are probably at least US$15m. The society has grown fat on the profits and is keen not only to keep the profits coming but also to exploit the brand. This has led to tensions between the journal and the society, and those tensions were in many ways the undoing of and , the successors to Relman. Both Angel and Kassirer after leaving the journal published books bemoaning the excessive influence of the drug industry, ... while the society appointed a new editor, , who was depicted by some as a creature of the industry. ... He had had financial connections with 21 drug companies between 1994 and 2000."